{
  "id": 14450970,
  "title": "Bernstein reiterates Linde stock rating on growth outlook",
  "url": "https://urgent.news/2026/10/14/bernstein-reiterates-linde-stock-rating-on-growth-outlook",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T12:48:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/bernstein-reiterates-linde-stock-rating-on-growth-outlook-93CH-4949280"
  },
  "original_language": "en",
  "account": "Bernstein SocGen Group maintained its Outperform rating and $563 price target on Linde (NASDAQ: LIN) stock, citing a positive long-term outlook. Analyst James Hooper highlighted the company's stability as a key player in the Chemicals industry, with a solid Financial Health score of GOOD. While the stock currently trades at $492, Bernstein believes it has upside potential of about 14% based on the price target. However, the firm is skeptical about Linde's ability to generate 8-12% adjusted earnings per share growth excluding macro and foreign exchange factors in the near term. The company's future may depend on a strategic decision regarding Lincare, its respiratory homecare unit, which Bernstein suggests should be sold without major fixes. Hooper predicts that the stock may recover to the 8-12% range following a potential resolution of this issue or through project wins. Recent analyst reports from UBS and KeyBanc also underscored Linde's growth prospects in healthcare and space markets, bolstering Bernstein's confidence in the company's future performance.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}